Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
50-81-7
Molecular formula
C6H8O6
Molecular weight
176.12 g/mol
Drug class
Vitamin C (ascorbic acid)water-soluble vitamin and reducing agent
Mechanism of action
Acts as an electron donor and cofactor for several dioxygenases, including prolyl and lysyl hydroxylases required for collagen synthesis, and enzymes involved in carnitine and catecholamine biosynthesis. It also functions as an antioxidant and supports normal immune function.
Indications / reported uses
Prevention and treatment of vitamin C deficiency and scurvy
Supplementation when dietary intake or absorption is inadequate; use for other conditions should not be inferred from nutritional or biochemical effects alone
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ascorbic Acid Environmental Risk Assessment (ERA) (the Ascorbic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.